Betta Pharmaceuticals Co., Ltd. (SHE:300558)
China · Delayed Price · Currency is CNY 46.22
+0.52 (1.14%)
Feb 3, 2026, 1:35 PM CST
Betta Pharmaceuticals Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Net Income | 303.28 | 402.57 | 348.03 | 145.42 | 383.07 | 606.36 |
Depreciation & Amortization | 371.97 | 371.97 | 303.49 | 253.7 | 174.46 | 155.16 |
Other Amortization | - | - | - | - | - | 0.7 |
Loss (Gain) From Sale of Assets | 0.59 | 0.59 | 0.01 | -88.61 | -0.07 | 1.7 |
Asset Writedown & Restructuring Costs | 28.05 | 28.05 | 1.07 | 3.01 | 0.03 | 10.25 |
Loss (Gain) From Sale of Investments | 40.97 | 40.97 | 13.67 | 20.62 | -15.96 | -292.66 |
Provision & Write-off of Bad Debts | -6.29 | -6.29 | 5.43 | 1.44 | - | - |
Other Operating Activities | -35.17 | 28.44 | 37.19 | 166.66 | 16.53 | 43.01 |
Change in Accounts Receivable | 156.53 | 156.53 | 174.2 | -198.29 | -181.6 | -15.65 |
Change in Inventory | 37.42 | 37.42 | 44.67 | -78.85 | -104.73 | -55.36 |
Change in Accounts Payable | -95.11 | -95.11 | 14.71 | -9.1 | 205.07 | 141.27 |
Change in Other Net Operating Assets | -57.13 | -57.13 | -16.46 | 132.53 | 75.97 | 62.53 |
Operating Cash Flow | 748.26 | 911.17 | 914.23 | 306.74 | 526.63 | 646.02 |
Operating Cash Flow Growth | -36.89% | -0.33% | 198.05% | -41.75% | -18.48% | 16.38% |
Capital Expenditures | -701.28 | -827.59 | -1,096 | -1,011 | -758.38 | -685.84 |
Sale of Property, Plant & Equipment | 0.02 | 0.14 | 22.21 | 0.69 | 0.24 | 1.55 |
Cash Acquisitions | - | - | - | - | -190.36 | - |
Divestitures | - | - | - | - | - | 259.75 |
Investment in Securities | -250.22 | -174.24 | -431.65 | -314.49 | -33.62 | -328.87 |
Other Investing Activities | 1 | - | - | - | - | 635.2 |
Investing Cash Flow | -950.48 | -1,002 | -1,505 | -1,324 | -982.13 | -118.21 |
Long-Term Debt Issued | - | 644.75 | 1,890 | 1,036 | - | 332.6 |
Long-Term Debt Repaid | - | -663.76 | -515.82 | -8.77 | -6.88 | -970 |
Net Debt Issued (Repaid) | 125.7 | -19.01 | 1,374 | 1,027 | -6.88 | -637.4 |
Issuance of Common Stock | 92.17 | - | 60.79 | 53.78 | 76.7 | 1,067 |
Common Dividends Paid | -182.85 | -150.87 | -110.28 | -139.52 | -137.64 | -119.7 |
Other Financing Activities | -23.32 | -21.5 | -716.49 | - | -27.73 | 5 |
Financing Cash Flow | 11.7 | -191.38 | 608.19 | 941.52 | -95.56 | 314.49 |
Foreign Exchange Rate Adjustments | 9.51 | 1.59 | 3.74 | 15.38 | -2.9 | -17.65 |
Net Cash Flow | -181.01 | -280.31 | 20.71 | -60.7 | -553.96 | 824.65 |
Free Cash Flow | 46.98 | 83.58 | -181.79 | -703.8 | -231.75 | -39.81 |
Free Cash Flow Growth | -84.88% | - | - | - | - | - |
Free Cash Flow Margin | 1.44% | 2.89% | -7.40% | -29.61% | -10.32% | -2.13% |
Free Cash Flow Per Share | 0.11 | 0.20 | -0.43 | -1.69 | -0.56 | -0.10 |
Cash Income Tax Paid | 215.07 | 116.65 | 94.58 | 111.5 | 152.36 | 98.57 |
Levered Free Cash Flow | -395.06 | -217.99 | -963.4 | -121.69 | -202.98 | -208.4 |
Unlevered Free Cash Flow | -350.4 | -189.56 | -929.06 | 0.69 | -193.12 | -183.49 |
Change in Working Capital | 44.88 | 44.88 | 205.34 | -195.49 | -31.44 | 121.51 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.